EZH2 and small cell lung carcinoma: Among validated results for multiple associated GMDs in Additional file 18: Table S18, we note multiple correlations involving the KMT2A (MLL) gene which is frequently mutated in SCLC, and EZH2, an important epigenetic drug target in SCLC, pharmacologic inhibition of which suppresses SCLC growth and chemoresistance [144–146].